Health-care companies ticked down amid mixed fortunes for the sector.
BioCryst Pharmaceuticals shares surged after the biotech firm said it would turn a profit in 2025, a year earlier than anticipated, amid robust demand for Oraldeyo, a treatment for rare disease hereditary angioedema.
BioNTech, the German biotech firm that rose to fame when it partnered with Pfizer on a Covid 19 vaccine, logged a hefty first-quarter loss and said it would focus on promising oncology programs from now on, citing risks to its current franchise from public policy and opinion.
Henry Schein's first-quarter net income rose and the company backed its 2025 adjusted earnings projection as increased doctor-office visits buoyed medical sales, offsetting weakness in demand for dental-supply sales and the impact of a strong dollar.
Health insurer UnitedHealth Group said it now has a thousand artificial-intelligence applications in production.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
05-05-25 1756ET
